Informationen: Dieses ist nicht die aktuellste Version des Datenmodells. Eine Versionsübersicht finden Sie links unter Versionen. Die aktuellste Version finden Sie hier.
Informationen:
Fehler:
ID
16822
Beschreibung
HLA typing results of patient and donor should be attached and sent: - to your NATIONAL REGISTRY if - you normally report to your National Registry and - you are based in the Netherlands, Switzerland, Turkey or the UK - to the EBMT REGISTRY OFFICE in London for any other centre Contact: Shelley Hewerdine EBMT Registry Office 4th Floor, Tabard House Guy's Hospital Great Maze Pond London SE1 9RT United Kingdom Phone: 00 44-207-188-8409 Fax: 00 44-207-188-8411 Email: shelley.hewerdine@ebmt.org
Stichworte
Versionen (4)
- 09.08.16 09.08.16 -
- 23.09.16 23.09.16 -
- 24.09.16 24.09.16 -
- 20.09.21 20.09.21 -
Hochgeladen am
9. August 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 3.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
100days past HSCT EBMT
20pp 100days past HSCT 02MED
- StudyEvent: ODM
Ähnliche Modelle
20pp 100days past HSCT 02MED
- StudyEvent: ODM
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
EBMT Code (CIC)
Item
EBMT Code (CIC)
text
Klinik
Item
Hospital
text
C0019994 (UMLS CUI [1])
Unit
Item
Unit
text
Contact person
Item
Contact person
text
Phone
Item
Phone
text
Fax
Item
Fax
text
e-mail
Item
e-mail
text
Date of this report
Item
Date of this report
date
C1302584 (UMLS CUI [1])
Item
Patient following national / international study / trial
integer
C1997894 (UMLS CUI [1])
Code List
Patient following national / international study / trial
CL Item
no (1)
CL Item
yes (2)
CL Item
unknown (3)
Name of study / trial
Item
Name of study / trial
text
Hospital Unique Patient Number/Code
Item
Hospital Unique Patient Number/Code
text
Initials
Item
Initials (first name(s) _family name(s))
text
PersonBirthDate
Item
Date of Birth
date
C0027361 (UMLS CUI [1,1])
C0005615 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0005615 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
CL Item
Male (1)
CL Item
Female (2)
Date of initial diagnosis
Item
Date of initial diagnosis
date
C2316983 (UMLS CUI [1])
PRIMARY DISEASE DIAGNOSIS
Item
PRIMARY DISEASE DIAGNOSIS
text
CL Item
Karnofsky (1)
CL Item
Lansky (2)
CL Item
10 (1)
CL Item
100 (10)
CL Item
20 (2)
CL Item
30 (3)
CL Item
40 (4)
CL Item
50 (5)
CL Item
60 (6)
CL Item
70 (7)
CL Item
80 (8)
CL Item
90 (9)
CL Item
Autologous (1)
CL Item
Allogeneic (2)
CL Item
Negative (Negative )
CL Item
Positive (Positive)
CL Item
Not evaluated (Not evaluated )
CL Item
Unknown (Unknown)
Multiple donors/products
Item
Multiple donors/products
boolean
Multiple donors/products
Item
if yes, Number (including multiple CB units or different stem cell products from same donor)
text
CL Item
Bone Marrow VBMSC (Bone Marrow VBMSC )
CL Item
Peripheral Blood VPBSC (Peripheral Blood VPBSC)
CL Item
Cord Blood VCBSC (Cord Blood VCBSC )
CL Item
Other (Other)
Source of Stem Cells
Item
if other, please specify
text
Donor ID
Item
Donor ID
text
C1718162 (UMLS CUI [1])
CL Item
N/A (1)
CL Item
Syngeneic (monozygotic twin) (Syngeneic (monozygotic twin))
CL Item
HLA-identical sibling (may include non-monozygotic twin) (HLA-identical sibling (may include non-monozygotic twin) )
CL Item
HLA-matched other relative (HLA-matched other relative)
CL Item
HLA-mismatched relative (HLA-mismatched relative)
CL Item
Unrelated donor (Unrelated donor)
CL Item
1 HLA antigen mismatch (1)
CL Item
> 2 HLA antigen mismatch (2)
Name of donor registry/CB Bank
Item
Name of donor registry/CB Bank
text
BMDW/WMDA code (up to 4 characters)
Item
BMDW/WMDA code (up to 4 characters)
text
CL Item
match (0)
CL Item
one mismatch (1)
CL Item
2 mismatches (2)
CL Item
not done (ND)
CL Item
match (0)
CL Item
one mismatch (1)
CL Item
2 mismatches (2)
CL Item
not done (ND)
CL Item
match (0)
CL Item
one mismatch (1)
CL Item
2 mismatches (2)
CL Item
not done (ND)
CL Item
match (0)
CL Item
one mismatch (1)
CL Item
2 mismatches (2)
CL Item
not done (ND)
CL Item
match (0)
CL Item
one mismatch (1)
CL Item
2 mismatches (2)
CL Item
not done (ND)
CL Item
match (0)
CL Item
one mismatch (1)
CL Item
2 mismatches (2)
CL Item
not done (ND)
CL Item
Male (Male )
CL Item
Female (Female)
CL Item
Negative (1)
CL Item
Positive (2)
CL Item
Not evaluated (3)
CL Item
Unknown (4)
Graft manipulation ex-vivo (including T-cell depletion) other than for RBC removal or volume reduction
Item
Graft manipulation ex-vivo (including T-cell depletion) other than for RBC removal or volume reduction
boolean
Chronological number of HSCT for this patient?
Item
Chronological number of HSCT for this patient?
text
If >1, date of last HSCT before this one
Item
If >1, date of last HSCT before this one
date
CL Item
Allo (Allo )
CL Item
Auto (Auto )
CL Item
N/A (N/A)
HSCT part of a planned multiple graft protocol?
Item
HSCT part of a planned multiple graft protocol?
boolean
Preparative (conditioning) regimen given?
Item
Preparative (conditioning) regimen given?
boolean
Was this intended to be myeloablative?
Item
Was this intended to be myeloablative?
boolean
CL Item
Age of recipient (Age of recipient)
CL Item
Comorbid conditions (Comorbid conditions)
CL Item
Prior HSCT (Prior HSCT)
CL Item
Protocol driven REASRIOT (Protocol driven REASRIOT)
CL Item
Other (Other)
Reason
Item
if other reason, please specify
text
Ara-C (cytarabine)
Item
Ara-C (cytarabine)
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
ALG, ATG (ALS, ATS)
Item
ALG, ATG (ALS, ATS)
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
CL Item
Horse (1)
CL Item
Rabbit (2)
CL Item
Other (3)
Animal origin
Item
Animal origin if other, please specify
text
Bleomycin
Item
Bleomycin
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Busulfan
Item
Busulfan
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
CL Item
Oral (1)
CL Item
IV (2)
CL Item
Both (3)
BCNU
Item
BCNU
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Bexar (radiolabelled MoAB)
Item
Bexar (radiolabelled MoAB)
float
CL Item
mCi (1)
CL Item
MBq (2)
CCNU
Item
CCNU
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Campath (antiCD52)
Item
Campath (antiCD52)
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Carboplatin
Item
Carboplatin
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Cisplatin
Item
Cisplatin
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Corticosteroids
Item
Corticosteroids
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Cyclophosphamide
Item
Cyclophosphamide
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Daunorubicin
Item
Daunorubicin
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Doxorubicin (adriamycine)
Item
Doxorubicin (adriamycine)
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Etoposide (VP16)
Item
Etoposide (VP16)
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Fludarabine
Item
Fludarabine
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Gemtuzumab
Item
Gemtuzumab
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Idarubicin
Item
Idarubicin
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Ifosfamide
Item
Ifosfamide
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Imatinib mesylate
Item
Imatinib mesylate
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Melphalan
Item
Melphalan
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Mitoxantrone
Item
Mitoxantrone
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Paclitaxel
Item
Paclitaxel
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Rituximab (mabthera, antiCD20)
Item
Rituximab (mabthera, antiCD20)
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Teniposide
Item
Teniposide
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Thiotepa
Item
Thiotepa
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Zevalin (radiolabelled MoAB)
Item
Zevalin (radiolabelled MoAB)
float
CL Item
mCi (1)
CL Item
MBq (2)
Other radiolabelled MoAB
Item
Other radiolabelled MoAB
float
CL Item
mCi (1)
CL Item
MBq (2)
Other radiolabelled MoAB
Item
if other, please specify
text
Other MoAB
Item
Other MoAB
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Other
Item
Other
float
CL Item
mg/m2 (1)
CL Item
mg/Kg (2)
Total body irradiation
Item
Total body irradiation
boolean
C0043162 (UMLS CUI [1])
Total Body Irradiation
Item
if yes, please specify value
text
TLI, TNI, TAI
Item
TLI, TNI, TAI
boolean
TLI, TNI, TAI
Item
if yes, please specify value
text
GvHD prophylaxis or preventive treatment
Item
GvHD prophylaxis or preventive treatment (Allografts only)
boolean
CL Item
Drugs (Immunosuppressive chemo) VAGVHDP5 (1)
CL Item
ALG, ALS, ATG, ATS (given after day 0) (2)
CL Item
Anti CD25 (MoAB in vivo) (3)
CL Item
Campath (MoAB in vivo; can be "in the bag") (4)
CL Item
Corticosteroids (5)
CL Item
Cyclosporine (6)
CL Item
Cyclophosphamide (given after day 0) (7)
CL Item
Etanercept (MoAB in vivo) (8)
CL Item
FK 506 (Tacrolimus, Prograf) (9)
CL Item
Infliximab (MoAB in vivo) (10)
CL Item
Methotrexate (11)
CL Item
Mycophenolate (MMF) (12)
CL Item
Sirolimus (13)
CL Item
Other monoclonal antibody (in vivo), (14)
CL Item
specify (15)
CL Item
Other agent (in vivo), specify (16)
CL Item
Extracorporeal photopheresis (ECP) (17)
CL Item
Other, specify (18)
GvHD prophylaxis or preventive treatment
Item
if other agent, please specify
text
GvHD prophylaxis or preventive treatment
Item
if other, please specify
text
GvHD prophylaxis or preventive treatment
Item
if Other monoclonal antibody, please specify
text
Item
Absolute neutrophil count (ANC) recovery (engraftment) (Neutrophils >0.5X109 /L)
integer
Code List
Absolute neutrophil count (ANC) recovery (engraftment) (Neutrophils >0.5X109 /L)
CL Item
No (1)
CL Item
Yes (2)
CL Item
Lost fraft (3)
CL Item
Never below (4)
CL Item
Unknown (5)
Date of last assessment
Item
Date of last assessment
date
Date of ANC recovery
Item
Date of ANC recovery
date
Date of last assessment
Item
Date of last assessment
date
CL Item
0 (none) (1)
CL Item
I (2)
CL Item
II (3)
CL Item
III (4)
CL Item
IV (5)
CL Item
Present but grade unknown (6)
CL Item
Not evaluated (7)
Cell infusion (CI)
Item
Cell infusion (CI)
boolean
Date of first infusion
Item
Date of first infusion
date
CL Item
Lymphocyte (DLI) (1)
CL Item
Mesenchymal (2)
CL Item
Fibroblasts (3)
CL Item
Dendritic cells (4)
CL Item
Other (5)
Type of cell(s): (check all that apply)
Item
if other, please specify
text
Chronological no. of CI for this patient
Item
Chronological no. of CI for this patient
text
Item
Indication (check all that apply)
text
C3146298 (UMLS CUI [1,1])
C0302189 (UMLS CUI [1,2])
C0302189 (UMLS CUI [1,2])
CL Item
Loss/decreased chimaerism (Loss/decreased chimaerism)
CL Item
Mixed chimaerism (Mixed chimaerism)
CL Item
Other (Other)
CL Item
Planned/ protocol (Planned/ protocol)
CL Item
Prophylactic (Prophylactic)
CL Item
Treatment for disease (Treatment for disease)
CL Item
Treatment of GvHD (Treatment of GvHD)
CL Item
Treatment PTLD, EBV, lymphoma (Treatment PTLD, EBV, lymphoma)
CL Item
Treatment viral infection (Treatment viral infection)
Indication:
Item
if other, please specify
text
Infusion count
Item
Number of infusions within 10 weeks (count only infusions that are part of same regimen and given for the same indication)
float
C0574032 (UMLS CUI [1,1])
C0750480 (UMLS CUI [1,2])
C0750480 (UMLS CUI [1,2])
CL Item
No (1)
CL Item
Yes: Planned (planned before HSCT took place) (2)
CL Item
Yes: Not planned (for relapse/progression or persistent disease) (3)
CL Item
Unknown (4)
Item
Best disease status (response) after HSCT (prior to treatment modification in response to a post HSCT disease assessment)
integer
Code List
Best disease status (response) after HSCT (prior to treatment modification in response to a post HSCT disease assessment)
CL Item
Continued complete remission (CCR) (1)
CL Item
CR achieved: Date achieved (2)
CL Item
Never in CR: Date assessed (3)
CL Item
Not evaluated (4)
CR achieved: Date achieved
Item
CR achieved: Date achieved
date
Never in CR: Date assessed
Item
Never in CR: Date assessed
date
Date of last follow up or death
Item
Date of last follow up or death
date
C3694716 (UMLS CUI [1,1])
C0011065 (UMLS CUI [1,2])
C0011065 (UMLS CUI [1,2])
CL Item
No (No)
CL Item
Yes (Yes)
CL Item
Continuous progression since HSCT (Continuous progression since HSCT)
Date assessed
Item
Date assessed
date
Date first seen
Item
Date first seen
date
Item
Relapse/progression detected by clinical/haematological method
text
Code List
Relapse/progression detected by clinical/haematological method
CL Item
No (No)
CL Item
Yes (Yes)
CL Item
Mot evaluated (Mot evaluated)
Date assessed
Item
Date assessed
date
Date first seen
Item
Date first seen
date
Item
Relapse/progression detected by cytogenetic method
integer
Code List
Relapse/progression detected by cytogenetic method
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
Date assessed
Item
Date assessed
date
Date first seen
Item
Date first seen
date
Item
Relapse/progression detected by molecular method
integer
Code List
Relapse/progression detected by molecular method
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
Date assessed
Item
Date assessed
date
Date first seen
Item
Date first seen
date
Was disease detected by clinical/haematological method?:
Item
Was disease detected by clinical/haematological method?:
date
Last date assessed
Item
Last date assessed
date
Item
Was disease detected by cytogenetic/FISH method?:
integer
Code List
Was disease detected by cytogenetic/FISH method?:
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
Considered disease relapse/progression
Item
Considered disease relapse/progression
boolean
Last date assessed
Item
Last date assessed
date
CL Item
Alive (Alive )
CL Item
Dead (Dead )
CL Item
Died before HSCT (Died before HSCT)
Check here if patient lost to follow up
Item
Check here if patient lost to follow up
boolean
CL Item
Relapse or Progression (if indication: primary disease) (1)
CL Item
HSCT related (if applicable) (2)
CL Item
Cell Therapy (3)
CL Item
Other (4)
CL Item
Unknown (5)
CL Item
GVHD GVH (1)
CL Item
Cardiac Toxicity CTX (2)
CL Item
Rejection/Poor graft function REJ (3)
CL Item
Infection INF (4)
CL Item
Pulmonary toxicity PTX (5)
CL Item
Veno occlusive disorder (6)
CL Item
Other (7)
DATE OF NEXT HSCT
Item
Date of this HSCT
date
EBMT Code (CIC):
Item
EBMT Code (CIC):
text
Hospital
Item
Name of the hospital
text
C0019994 (UMLS CUI [1])
Unit:
Item
Unit:
text
Contact person
Item
Contact person
text
e-mail
Item
e-mail
text
Has the HSCT been registered in the EBMT database ?
Item
Has the HSCT been registered in the EBMT database ?
boolean
C0421512 (UMLS CUI [1])
Has the HSCT been registered in the EBMT database ?
Item
If Yes: UIC number
text
Hospital Unique Patient Number/ Code
Item
Hospital Unique Patient Number/ Code
text
Initials
Item
Initials
text
Gender
Item
Gender
text
Date of Birth
Item
Date of Birth
date
Date of HSCT
Item
Date of HSCT
date
Donor ID
Item
Donor ID
text
Item Group
PATIENT ETHNIC OR RACIAL ORIGIN
CL Item
Hispanic or Latino (Hispanic or Latino )
CL Item
Not Hispanic or Latino (Not Hispanic or Latino)
CL Item
White (White)
CL Item
Black (Black)
CL Item
Asian ETHNIC12 (Asian ETHNIC12 )
CL Item
American Indian/Alaska Native (American Indian/Alaska Native )
CL Item
Native Hawaiian/Other Pacific Islander (Native Hawaiian/Other Pacific Islander)
CL Item
Alkylating agent/radiation-related (Alkylating agent/radiation-related)
CL Item
Topoisomerase II inhibitor-related (Topoisomerase II inhibitor-related)
CL Item
Unknown (Unknown)
Item
MOLECULAR BIOLOGYCompulsory for CIBMTR Research centres. Fill only for MPS. Janus kinase 2 (jak2)
integer
Code List
MOLECULAR BIOLOGYCompulsory for CIBMTR Research centres. Fill only for MPS. Janus kinase 2 (jak2)
CL Item
Absent (1)
CL Item
Present (2)
CL Item
Unknown (3)
THERAPY GIVEN PRIOR TO THIS HSCT
Item
THERAPY GIVEN PRIOR TO THIS HSCT
boolean
THERAPY GIVEN PRIOR TO THIS HSCT
Item
Date started
date
Tyrosine kinase receptor antagonist given
Item
Tyrosine kinase receptor antagonist given
boolean
CL Item
Imatinib mesylate (Gleevec, Glivec) (1)
CL Item
Dasatinib (Sprycel) (2)
CL Item
Nilotinib (Tasigna) (3)
CL Item
Other (4)
CL Item
Combination chemotherapy (Combination chemotherapy )
CL Item
Hydroxyurea (Hydroxyurea)
CL Item
Interferon (Interferon)
CL Item
Other (Other)
Were there any clinically significant co-existing disease or organ impairment at time of patient assessment prior to preparative (conditioning) regimen?
Item
Were there any clinically significant co-existing disease or organ impairment at time of patient assessment prior to preparative (conditioning) regimen?
boolean
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
Item
limited food choices due to celiac sprue or inflammatory bowel disease
integer
C0021390 (UMLS CUI [1])
CL Item
Combination chemotherapy (Combination chemotherapy )
CL Item
Hydroxyurea (Hydroxyurea)
CL Item
Interferon (Interferon)
CL Item
Other (Other)
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
Other Comorbidity
Item
if other Comorbidity, please specify
text
Item Group
GRAFT PERFORMANCE Compulsory for CIBMTR Research centres
CL Item
No (No)
CL Item
Yes (Yes)
CL Item
Never below this lever (Never below this lever)
CL Item
Unknown (Unknown)
Date Platelets > 20 x 10 9 /l
Item
Date Platelets > 20 x 10 9 /l
date
Item Group
GRAFT PERFORMANCE
Item
Platelet reconstitution (Platelets >20X109 /L; first of 3 consecutive days)
text
Code List
Platelet reconstitution (Platelets >20X109 /L; first of 3 consecutive days)
CL Item
No (No)
CL Item
Yes (Yes)
CL Item
Never below this lever (Never below this lever)
CL Item
Unknown (Unknown)
Date Platelets > 20 x 10 9 /l
Item
Date Platelets > 20 x 10 9 /l
date
PLANNED THERAPY GIVEN AFTER THIS HSCT
Item
PLANNED THERAPY GIVEN AFTER THIS HSCT, Date started
date
Chemo/drug
Item
Chemo/drug
boolean
CL Item
Imatinib mesylate (Gleevec, Glivec) (Imatinib mesylate (Gleevec, Glivec))
CL Item
Dasatinib (Sprycel) (Dasatinib (Sprycel))
CL Item
Nilotinib (Tasigna) (Nilotinib (Tasigna))
CL Item
Bortezomib (Velcade) (Bortezomib (Velcade))
CL Item
Intrathecal chemotherapy (Intrathecal chemotherapy)
CL Item
Lenalidomide (Revlimid) (Lenalidomide (Revlimid))
CL Item
Rituximab (Rituxan, mabthera) (Rituximab (Rituxan, mabthera))
CL Item
Velafermin (FGF) (Velafermin (FGF))
CL Item
Lepivance (KGF, palifermin) (Lepivance (KGF, palifermin))
CL Item
Thalidomide (Thalidomide)
CL Item
Other (Other)
Radiotherapy
Item
Radiotherapy
boolean
Item Group
HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 1
EBMT Centre Identification Code (CIC)
Item
EBMT Centre Identification Code (CIC)
text
C2348585 (UMLS CUI [1])
Hospital Unique Patient Number/Code (UPN)
Item
Hospital Unique Patient Number/Code (UPN)
text
Date of Initial Diagnosis
Item
Date of Initial Diagnosis
date
CL Item
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 (1)
CL Item
AML with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); CBFB-MYH11 (2)
CL Item
Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML/RARA (3)
CL Item
AML with t(9;11) (p22;q23); MLLT 3-MLL (4)
CL Item
AML with myelodysplasia related changes (5)
CL Item
(with multilineage dysplasia; w/o MDS or MDS/MPN antecedents) (6)
CL Item
AML with t(6;9) (p23;q24); DEK-NUP214 (7)
CL Item
AML with inv(3) (q21;q26.2) or t(3;3) (q21;q26.2); RPN1-EVI1 (8)
CL Item
AML (megakaryoblastic) with t(1;22) (p13;q13); RBM15-MKL1 (9)
CL Item
AML with minimal differentiation (FAB M0) (1)
CL Item
AML without maturation (FAB M1) (2)
CL Item
AML with maturation (FAB M2) (3)
CL Item
Acute myelomonocytic leukaemia (FAB M4) (4)
CL Item
Acute monoblastic and monocytic leukaemia (FAB M5) (5)
CL Item
Acute erythroid leukaemia (erythroid/myeloid and pure erythroleukaemia) (FAB M6) (6)
CL Item
Acute megakaryoblastic leukaemia (FAB M7) (7)
CL Item
Acute basophilic leukaemia (8)
CL Item
Acute panmyelosis with myelofibrosis (9)
CL Item
Myeloid sarcoma (10)
CL Item
Myeloid proliferations related to Down syndrome (11)
CL Item
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) (12)
CL Item
Acute myeloid leukaemia not otherwise specified or other (13)
CL Item
B lymphoblastic leukaemia/lymphoma NOS (old Precursor B-cell ALL) (1)
CL Item
with t(9;22)(q34;q11.2); BCR-ABL1 (2)
CL Item
with t(v;11q23); MLL rearranged (3)
CL Item
with t(12;21)(p13;q22); TEL-AML1 (ETV-UNX1) (4)
CL Item
with hyperdiploidy (5)
CL Item
with hypodiploidy (6)
CL Item
with t(5;14)(q31;q32); IL3-IGH (7)
CL Item
with t(1;19)(q23;p13.3); E2A-PBX1 (8)
CL Item
T lymphoblastic leukaemia/lymphoma (old precursor T-cell ALL) (9)
CL Item
Lymphoblastic leukaemia/lymphoma not otherwise specified or other (10)
CL Item
Transformed from MDS (1)
CL Item
Transformed from MD/MPN (2)
CL Item
Transformed from MPS (3)
CL Item
Yes: Disease related to prior exposure to therapeutic drugs or radiation (Yes: Disease related to prior exposure to therapeutic drugs or radiation)
CL Item
No (No)
CL Item
Unknown (Unknown)
Date of this HSCT
Item
Date of this HSCT
date
CL Item
Primary induction failure (1)
CL Item
Complete haematological remission (CR) (2)
CL Item
Relapse (3)
CL Item
Never treated (4)
CL Item
1st (1)
CL Item
2nd (2)
CL Item
3rd or higher (3)
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
CL Item
Unknown (4)
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
CL Item
Unknown (4)
Item Group
HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 2
EBMT Centre Identification Code (CIC)
Item
EBMT Centre Identification Code (CIC)
text
C2348585 (UMLS CUI [1])
Hospital Unique Patient Number/Code
Item
Hospital Unique Patient Number/Code
text
Date of initial diagnosis
Item
Date of initial diagnosis
date
C2316983 (UMLS CUI [1])
Item Group
Classification
Item
At least one investigation must be positive: Translocation (9;22)
text
C3897138 (UMLS CUI [1])
CL Item
Absent (Absent)
CL Item
Not evaluated (Not evaluated)
CL Item
Present (Present)
CL Item
Absent (Absent)
CL Item
Not evaluated (Not evaluated)
CL Item
Present (Present)
Date of this HSCT
Item
Date of this HSCT
date
CL Item
Chronic phase (CP) (1)
CL Item
Accelerated phase (2)
CL Item
Blast crisis (3)
CL Item
1st (1)
CL Item
2nd (2)
CL Item
3rd or higher (3)
CL Item
Yes (Yes )
CL Item
No (No )
CL Item
Not evaluated (Not evaluated )
CL Item
Unknown (Unknown)
CL Item
Yes (1)
CL Item
No (2)
CL Item
Not evaluated (3)
CL Item
Unknown (4)
CL Item
Yes (1)
CL Item
No (2)
CL Item
Not evaluated (3)
CL Item
Unknown (4)
CL Item
Chronic lymphocytic leukaemia (CLL) (1)
CL Item
Prolymphocytic Leukaemia (2)
CL Item
PLL, B-cell (3)
CL Item
PLL, T-cell (4)
CL Item
Hairy Cell Leukaemia (5)
CL Item
Other leukaemia (6)
Date of this HSCT
Item
Date of this HSCT
date
CL Item
Complete remission (CR) (Complete remission (CR))
CL Item
Partial remission (PR) Nodular Partial remission (nPR) (Partial remission (PR) Nodular Partial remission (nPR))
CL Item
Relapse (Relapse)
CL Item
Progression (Progression)
CL Item
Never treated (Never treated)
CL Item
Stable disease/No response (Stable disease/No response)
Item Group
HSCT - Minimum Essential Data – A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 3
EBMT Centre Identification Code (CIC)
Item
EBMT Centre Identification Code (CIC)
text
C2348585 (UMLS CUI [1])
Hospital Unique Patient Number/Code
Item
Hospital Unique Patient Number/Code
text
Date of Initial Diagnosis
Item
Date of Initial Diagnosis
date
CL Item
Splenic marginal zone lymphoma (Splenic marginal zone lymphoma)
CL Item
Extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT) (Extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT))
CL Item
Nodal marginal zone lymphoma (Nodal marginal zone lymphoma)
CL Item
Lymphoplasmacytic lymphoma (LPL) (Lymphoplasmacytic lymphoma (LPL))
CL Item
Waldenstrom macroglobulinaemia (LPL with monoclonal IgM) (Waldenstrom macroglobulinaemia (LPL with monoclonal IgM))
CL Item
Follicular lymphoma (Follicular lymphoma)
CL Item
Primary cutaneous follicle centre lymphoma (Primary cutaneous follicle centre lymphoma)
CL Item
Mantle cell lymphoma (Mantle cell lymphoma)
CL Item
Diffuse large B-cell lymphoma (DLBCL), (NOS) (Diffuse large B-cell lymphoma (DLBCL), (NOS))
CL Item
T-cell/hystiocyte rich large B cell lymphoma (T-cell/hystiocyte rich large B cell lymphoma)
CL Item
Primary DLBCL of the CNS (Primary DLBCL of the CNS)
CL Item
Primary cutaneous DLBCL, leg type (Primary cutaneous DLBCL, leg type)
CL Item
EBV positive DLBCL of the elderly (EBV positive DLBCL of the elderly)
CL Item
DLBCL associated with chronic inflammation (DLBCL associated with chronic inflammation)
CL Item
Lymphomatoid granulomatosis (Lymphomatoid granulomatosis)
CL Item
Primary mediastinal (thymic) large B-cell lymphoma (Primary mediastinal (thymic) large B-cell lymphoma)
CL Item
Intravascular large B-cell lymphoma (Intravascular large B-cell lymphoma)
CL Item
ALK positive large B-cell lymphoma (ALK positive large B-cell lymphoma)
CL Item
Plasmablastic lymphoma (Plasmablastic lymphoma)
CL Item
Large B-cell lymphoma arising in HHV8- associated multicentric Castleman disease (Large B-cell lymphoma arising in HHV8- associated multicentric Castleman disease)
CL Item
Primary effusion lymphoma (PEL) (Primary effusion lymphoma (PEL))
CL Item
Burkitt lymphoma (BL) (Burkitt lymphoma (BL))
CL Item
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (Intermediate DLCBL/BL) (B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (Intermediate DLCBL/BL))
CL Item
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma (Intermediate DLCBL/HD) (B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma (Intermediate DLCBL/HD))
CL Item
Other B-cell (Other B-cell)
CL Item
Grade I (1)
CL Item
Grade II (2)
CL Item
Grade III (3)
CL Item
Not evaluated (4)
CL Item
T-cell large granular lymphocytic leukaemia (1)
CL Item
Aggressive NK-cell leukaemia (2)
CL Item
Systemic EBV positive T-cell lymphoproliferative disease of childhood (3)
CL Item
Hydroa vacciniforme-like lymphoma (4)
CL Item
Adult T-cell leukaemia/lymphoma (5)
CL Item
Extranodal NK/T-cell lymphoma, nasal type (6)
CL Item
Enteropathy-associated T-cell lymphoma (7)
CL Item
Hepatosplenic T-cell lymphoma (8)
CL Item
Subcutaneous panniculitis-like T-cell lymphoma (9)
CL Item
Mycosis fungoides (MF) (10)
CL Item
Sézary syndrome (11)
CL Item
Lymphomatoid papulosis (12)
CL Item
Primary cutaneous anaplastic large cell lymphoma (13)
CL Item
Primary cutaneous gamma-delta T-cell lymphoma (14)
CL Item
Primary cutaneous CD8 positive aggressive epidermotropic cytotoxic T-cell lymphoma (15)
CL Item
Primary cutaneous CD4 positive small/medium T-cell lymphoma (16)
CL Item
Peripheral T-cell lymphoma, NOS (PTCL) (17)
CL Item
Angioimmunoblastic T-cell lymphoma (18)
CL Item
Anaplastic large-cell lymphoma (ALCL), ALK-positive (19)
CL Item
Anaplastic large-cell lymphoma (ALCL), ALK-negative (20)
CL Item
Other T-cell (21)
CL Item
Hodgkin (22)
CL Item
Nodular lymphocyte predominant (1)
CL Item
Classical predominant (2)
CL Item
Lymphocyte rich (3)
CL Item
Nodular sclerosis (4)
CL Item
Mixed cellularity (5)
CL Item
Lymphocyte depleted (6)
CL Item
Other (7)
Date of this HSCT
Item
Date of this HSCT
date
CL Item
Never treated (Never treated)
CL Item
Primary refractory (Primary refractory)
CL Item
Complete remission (CR) (Complete remission (CR))
CL Item
Confirmed (Confirmed )
CL Item
Unconfirmed (CRU*) (Unconfirmed (CRU*))
CL Item
1st Partial response (PR1) (1st Partial response (PR1))
CL Item
Partial response>1 (never in CR) (PR>1) (Partial response>1 (never in CR) (PR>1))
CL Item
Relapse (Relapse)
CL Item
Progression (Progression)
CL Item
1st (1)
CL Item
2nd (2)
CL Item
3nd or higher (3)
CL Item
Sensitive (Sensitive)
CL Item
Resistan (Resistan)
CL Item
Untreated (Untreated)
CL Item
Unknown (Unknown)
Item Group
HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 4
EBMT Centre Identification Code (CIC)
Item
EBMT Centre Identification Code (CIC)
text
C2348585 (UMLS CUI [1])
Hospital Unique Patient Number/Code
Item
Hospital Unique Patient Number/Code
text
Date of initial diagnosis
Item
Date of initial diagnosis
date
C2316983 (UMLS CUI [1])
CL Item
Refractory anaemia (without ring sideroblasts) RA (Refractory anaemia (without ring sideroblasts) RA)
CL Item
RA with ring sideroblasts (RARS) (RA with ring sideroblasts (RARS))
CL Item
MDS associated with isolated del(5q) (MDS associated with isolated del(5q))
CL Item
Refractory cytopenia with multilineage dysplasia (RCMD) (Refractory cytopenia with multilineage dysplasia (RCMD))
CL Item
RCMD with ringed sideroblasts (RCMD-RS) (RCMD with ringed sideroblasts (RCMD-RS))
CL Item
RA with excess of blasts-1 (RAEB-1) (RA with excess of blasts-1 (RAEB-1))
CL Item
RA with excess of blasts-2 (RAEB-2) (RA with excess of blasts-2 (RAEB-2))
CL Item
MDS Unclassifiable (MDS-U) (MDS Unclassifiable (MDS-U))
CL Item
Childhood myelodysplastic syndrome (Childhood myelodysplastic syndrome)
CL Item
RA (1)
CL Item
RARS (2)
CL Item
RAEB (3)
CL Item
RAEB in transformation (RAEB-t) (4)
CL Item
Unclassified (5)
CL Item
Primary refractory phase (no change) (1)
CL Item
Complete remission (CR) (2)
CL Item
Improvement but no CR (3)
CL Item
Relapse (after CR) (4)
CL Item
Progression/worse (5)
CL Item
Never treated (Supportive care or treatment without chemotherapy) (6)
CL Item
1st (1st)
CL Item
2nd (2nd)
CL Item
3rd or higher (3rd or higher)
Item Group
HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 5
EBMT Centre Identification Code (CIC)
Item
EBMT Centre Identification Code (CIC)
text
C2348585 (UMLS CUI [1])
Hospital Unique Patient Number/Code
Item
Hospital Unique Patient Number/Code
text
Date of Initial Diagnosis
Item
Date of Initial Diagnosis
date
CL Item
Chronic myelomonocytic leukaemia (CMMoL, CMML) (1)
CL Item
Juvenile myelomonocytic leukaemia (JCMMoL, JMML, JCML, JCMML) (2)
CL Item
Atypical CML ((t(9;22) negative and bcr/abl negative) (3)
CL Item
Chronic myelomonocytic leukaemia (CMMoL, CMML) (1)
CL Item
Juvenile myelomonocytic leukaemia (JCMMoL, JMML, JCML, JCMML) (2)
CL Item
Atypical CML ((t(9;22) negative and bcr/abl negative) (3)
CL Item
Transformed to AML: Date of transformation (4)
Date of this HSCT
Item
Date of this HSCT
date
Item
CMML (including Transformed to AML) / Atypical CML Status at HSCT
integer
Code List
CMML (including Transformed to AML) / Atypical CML Status at HSCT
CL Item
Primary refractory phase (no change) (1)
CL Item
Complete remission (CR) (2)
CL Item
Improvement but no CR (3)
CL Item
Relapse (after CR) (4)
CL Item
Progression/worse (5)
CL Item
1st (1st)
CL Item
2nd (2nd)
CL Item
3rd or higher (3rd or higher)
CL Item
Stable disease (SD) (1)
CL Item
Complete response (CR) (2)
CL Item
Minimal response (MR) (3)
CL Item
Partial response (PR) (4)
CL Item
Progression (PD) (5)
Item Group
HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 6
EBMT Centre Identification Code (CIC)
Item
EBMT Centre Identification Code (CIC)
text
C2348585 (UMLS CUI [1])
Hospital Unique Patient Number/Code
Item
Hospital Unique Patient Number/Code
text
Date of initial diagnosis
Item
Date of initial diagnosis
date
C2316983 (UMLS CUI [1])
CL Item
Chronic idiopathic myelofibrosis (primary myelofibrosis, fibrosis with myeloid metaplasia) (1)
CL Item
Polycythaemia vera (2)
CL Item
Essential or primary thrombocythaemia (3)
CL Item
Hyper eosinophilic syndrome (HES) (4)
CL Item
Chronic eosinophilic leukaemia (CEL) (5)
CL Item
Chronic neutrophilic leukaemia (6)
CL Item
Stem cell leukaemia-lymphoma syndrome (8p11 syndrome) (7)
CL Item
Systemic mastocytosis (8)
CL Item
MPS not otherwise specified (9)
CL Item
Other (10)
CL Item
Yes: Disease related to prior exposure to therapeutic drugs or radiation (1)
CL Item
No (2)
CL Item
Unknown (3)
Date of this HSCT
Item
Date of this HSCT
date
CL Item
Chronic idiopathic myelofibrosis (primary myelofibrosis, fibrosis with myeloid metaplasia) (1)
CL Item
Polycythaemia vera (2)
CL Item
Essential or primary thrombocythaemia (3)
CL Item
Hyper eosinophilic syndrome (HES) (4)
CL Item
Chronic eosinophilic leukaemia (CEL) (5)
CL Item
Chronic neutrophilic leukaemia (6)
CL Item
Stem cell leukaemia-lymphoma syndrome (8p11 syndrome) (7)
CL Item
Myelofibrosis transformed from Polycythaemia vera/ Essential thrombocythaemia (8)
CL Item
Transformed to AML (9)
CL Item
MPS not otherwise specified (10)
CL Item
Other (11)
CL Item
Classification at HSCT (Classification at HSCT)
CL Item
Primary refractory phase (no change) (Primary refractory phase (no change))
CL Item
Complete remission (CR) (Complete remission (CR))
CL Item
Improvement but no CR (Improvement but no CR)
CL Item
Relapse (after CR) (Relapse (after CR))
CL Item
Progression/worse (Progression/worse)
CL Item
Never treated (Supportive care or treatment without chemotherapy) (Never treated (Supportive care or treatment without chemotherapy))
CL Item
1st (1st)
CL Item
2nd (2nd)
CL Item
3rd or higher (3rd or higher)
Item Group
HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 7
EBMT Centre Identification Code (CIC)
Item
EBMT Centre Identification Code (CIC)
text
C2348585 (UMLS CUI [1])
Hospital Unique Patient Number/Code
Item
Hospital Unique Patient Number/Code
text
Date of Initial Diagnosis
Item
Date of Initial Diagnosis
date
CL Item
Multiple myeloma IgG (1)
CL Item
Multiple myeloma IgA (2)
CL Item
Multiple myeloma IgD (3)
CL Item
Multiple myeloma IgE (4)
CL Item
Multiple myeloma IgM (not Waldenstrom) (5)
CL Item
Multiple myeloma-light chain only (6)
CL Item
Multiple myeloma-non-secretory (7)
CL Item
Plasma cell leukaemia (8)
CL Item
Solitary plasmacytoma (9)
CL Item
Primary amyloidosis (10)
CL Item
POEMS (11)
CL Item
Monoclonal light and heavy chain deposition disease (LCDD/HCDD) (12)
CL Item
Other (13)
CL Item
Kappa (Kappa)
CL Item
Lambda (Lambda)
Item
SALMON & DURIE STAGE AT DIAGNOSIS (Multiple Myeloma only)
integer
Code List
SALMON & DURIE STAGE AT DIAGNOSIS (Multiple Myeloma only)
CL Item
I (I)
CL Item
II (II)
CL Item
III (III)
CL Item
A (A)
CL Item
B (B)
Date of this HSCT
Item
Date of this HSCT
date
CL Item
Never treated (Never treated)
CL Item
Stringent complete remission (sCR) (Stringent complete remission (sCR))
CL Item
Complete remission (CR) (Complete remission (CR))
CL Item
Very good partial remission (VGPR) (Very good partial remission (VGPR))
CL Item
Partial remission (PR) (Partial remission (PR))
CL Item
Relapse from CR (untreated) (Relapse from CR (untreated))
CL Item
Progression (Progression)
CL Item
No change / stable disease (No change / stable disease)
Item
NUMBER (complete for sCR, CR,VGPR, PR or relapse)
integer
CL Item
I (I)
CL Item
II (II)
CL Item
III (III)
CL Item
A (A)
CL Item
B (B)
Item Group
BONE MARROW FAILURE SYNDROMES including APLASTIC ANAEMIA (main disease code 7)ISMC
CL Item
Acquired Severe Aplastic Anaemia (SAA) (1)
CL Item
Amegakaryocytosis, acquired (not congenital) (2)
CL Item
Acquired Pure Red Cell Aplasia (PRCA) (not congenital) (3)
CL Item
Paroxysmal nocturnal haemoglobinuria (PNH) (4)
CL Item
Other acquired cytopenic syndrome (5)
CL Item
Secondary to hepatitis (1)
CL Item
Secondary to toxin/other drug (2)
CL Item
Idiopathic (3)
CL Item
Other (4)
CL Item
Amegakaryocytosis / thrombocytopenia (1)
CL Item
Fanconi anaemia (2)
CL Item
Diamond-Blackfan anaemia (congenital PRCA) (3)
CL Item
Shwachman-Diamond Syndrome (4)
CL Item
Other congenital anaemia (5)
Congenital
Item
if other, please specify
text
Date of this HSCT
Item
Date of this HSCT
date
CL Item
Thalassaemia (Thalassaemia)
CL Item
Sickle cell disease (Sickle cell disease)
CL Item
Other haemoglobinopathy (Other haemoglobinopathy)
HAEMOGLOBINOPATHY Classification
Item
if other, please specify
text
Date of this HSCT
Item
Date of this HSCT
date
Item Group
HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 8
EBMT Centre Identification Code (CIC)
Item
EBMT Centre Identification Code (CIC)
text
C2348585 (UMLS CUI [1])
Hospital Unique Patient Number/Code
Item
Hospital Unique Patient Number/Code
text
Date of initial diagnosis
Item
Date of initial diagnosis
date
C2316983 (UMLS CUI [1])
CL Item
No distant metastases (No distant metastases)
CL Item
Distant metastasis (Distant metastasis)
CL Item
O (1)
CL Item
I (2)
CL Item
II (3)
CL Item
III (4)
CL Item
Inflammatory (1)
CL Item
Non-inflammatory (2)
Date of this HSCT
Item
Date of this HSCT
date
CL Item
Adjuvant (Stage II, III only) (1)
CL Item
Never treated (upfront) (2)
CL Item
Primary refractory (3)
CL Item
Complete remission (CR) (4)
CL Item
1st Partial response (PR1) (5)
CL Item
Relapse (6)
CL Item
Confirmed (1)
CL Item
Unconfirmed (CRU*) (2)
CL Item
Unknown (3)
CL Item
Local (1)
CL Item
Metastatic (2)
Item
OTHER MALIGNANCIES (main disease code 5) Classification:
text
Code List
OTHER MALIGNANCIES (main disease code 5) Classification:
CL Item
Bone sarcoma (excluding Ewing sarcoma/PNET) (Bone sarcoma (excluding Ewing sarcoma/PNET))
CL Item
Central nervous system tumours (include CNS PNET) (Central nervous system tumours (include CNS PNET))
CL Item
Colorecta (Colorecta)
CL Item
Ewing sarcoma/PNET, extra-skeletal (Ewing sarcoma/PNET, extra-skeletal)
CL Item
Ewing sarcoma/PNET, skeletal (Ewing sarcoma/PNET, skeletal)
CL Item
Germ cell tumour, extragonadal only (Germ cell tumour, extragonadal only)
CL Item
Hepatobiliary (Hepatobiliary)
CL Item
Lung cancer, non-small cell (Lung cancer, non-small cell)
CL Item
Lung cancer, small cell (Lung cancer, small cell)
CL Item
Medulloblastoma (Medulloblastoma)
CL Item
Melanoma (Melanoma)
CL Item
Neuroblastoma (Neuroblastoma)
CL Item
Ovarian (Ovarian)
CL Item
Pancreas (Pancreas)
CL Item
Prostate (Prostate)
CL Item
Renal cell (Renal cell)
CL Item
Retinoblastoma (Retinoblastoma)
CL Item
Rhabdomyosarcoma (Rhabdomyosarcoma)
CL Item
Soft tissue sarcoma (Soft tissue sarcoma)
CL Item
Testicular (Testicular)
CL Item
Thymoma (Thymoma)
CL Item
Wilm tumour (Wilm tumour)
CL Item
Other (Other)
Classification
Item
if other, please specify
text
Date of this HSCT
Item
Date of this HSCT
date
CL Item
Adjuvant (Adjuvant)
CL Item
Never treated (upfront) (Never treated (upfront))
CL Item
Stable disease/no response (Stable disease/no response)
CL Item
Complete remission (CR) (Complete remission (CR))
CL Item
1st Partial response (PR1) (1st Partial response (PR1))
CL Item
Relapse (Relapse)
CL Item
Progressive disease (PD) (Progressive disease (PD))
CL Item
Confirmed (1)
CL Item
Unconfirmed (CRU complete response with persistent scan abnormalities of unknown significance) (2)
CL Item
1st (1)
CL Item
2nd (2)
CL Item
3rd or higher (3)
CL Item
Sensitive (1)
CL Item
Resistant (2)
CL Item
Untreated (3)
Item Group
HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 9
EBMT Centre Identification Code (CIC)
Item
EBMT Centre Identification Code (CIC)
text
C2348585 (UMLS CUI [1])
Hospital Unique Patient Number/Code
Item
Hospital Unique Patient Number/Code
text
Date of Initial Diagnosis
Item
Date of Initial Diagnosis
date
CL Item
Absence of T and B cells SCID (1)
CL Item
Kostmann syndrome-congenital neutropenia (2)
CL Item
Absence of T, normal B cell SCID (3)
CL Item
Leukocyte adhesion deficiencies (4)
CL Item
ADA deficiency (Adenosine deaminase deficiency) (5)
CL Item
Neutrophil actin deficiency (6)
CL Item
Ataxia telangiectasia (7)
CL Item
Omenn syndrome (8)
CL Item
Bare lymphocyte syndrome (9)
CL Item
PNP deficiency Purine nucleoside phosphorylase deficiency) (10)
CL Item
Cartilage hair hypoplasiaVD (11)
CL Item
Reticular dysgenesis (12)
CL Item
CD 40 Ligand deficiency (13)
CL Item
SCID other (14)
CL Item
Chediak-Higashi syndrome (15)
CL Item
SCID, unspecified (16)
CL Item
Chronic granulomatous disease (17)
CL Item
Wiskott Aldrich syndrome (18)
CL Item
Common variable immunodeficiency (19)
CL Item
X-linked lymphoproliferative syndrome (20)
CL Item
DiGeorge anomaly (21)
CL Item
Other (22)
CL Item
Immune deficiencies, not otherwise specified (23)
Date of this HSCT
Item
Date of this HSCT
date
Item
INHERITED DISORDERS OF METABOLISM (main disease code 8) DISMCLFD INHDIS Classification
integer
Code List
INHERITED DISORDERS OF METABOLISM (main disease code 8) DISMCLFD INHDIS Classification
CL Item
Adrenoleukodystrophy (1)
CL Item
Metachromatic leukodystrophy (2)
CL Item
Aspartyl glucosaminuria (3)
CL Item
Morquio (IV) (4)
CL Item
B-glucuronidase deficiency (VII) (5)
CL Item
Mucolipidoses, unspecified (6)
CL Item
Fucosidosis (7)
CL Item
Mucopolysaccharidosis (V) (8)
CL Item
Gaucher disease (9)
CL Item
Mucopolysaccharidosis, unspecified (10)
CL Item
Glucose storage disease (11)
CL Item
Niemann-Pick disease (Type A,B) (12)
CL Item
Hunter syndrome (II) (13)
CL Item
Niemann-Pick disease (Type C,D,E) (14)
CL Item
Hurler syndrome (IH) (15)
CL Item
Neuronal ceroid – lipofuscinosis (Batten disease) (16)
CL Item
T-cell disease (17)
CL Item
Polysaccharide hydrolase abnormalities, unspecified (18)
CL Item
Krabbe disease (globoid leukodystrophy) (19)
CL Item
Sanfilippo (III) (20)
CL Item
Lesch-Nyhan (HGPRT deficiency) (21)
CL Item
Scheie syndrome (IS) (22)
CL Item
Mannosidosis (23)
CL Item
Wolman disease (24)
CL Item
Maroteaux-Lamy (VI) (25)
CL Item
Other (26)
CL Item
Inherited disorders of metabolism, not otherwise specified (27)
Date of this HSCT
Item
Date of this HSCT
date
CL Item
Adrenoleukodystrophy (Adrenoleukodystrophy)
CL Item
Metachromatic leukodystrophy (Metachromatic leukodystrophy)
CL Item
Aspartyl glucosaminuria (Aspartyl glucosaminuria)
CL Item
Morquio (IV) (Morquio (IV))
CL Item
B-glucuronidase deficiency (VII) (B-glucuronidase deficiency (VII))
CL Item
Mucolipidoses, unspecified (Mucolipidoses, unspecified)
CL Item
Fucosidosis (Fucosidosis)
CL Item
Mucopolysaccharidosis (V) (Mucopolysaccharidosis (V))
CL Item
Gaucher disease (Gaucher disease )
CL Item
Mucopolysaccharidosis, unspecified (Mucopolysaccharidosis, unspecified)
CL Item
Glucose storage disease (Glucose storage disease)
CL Item
Niemann-Pick disease (Type A,B) (Niemann-Pick disease (Type A,B))
CL Item
Hunter syndrome (II) (Hunter syndrome (II))
CL Item
Niemann-Pick disease (Type C,D,E) (Niemann-Pick disease (Type C,D,E))
CL Item
Hurler syndrome (IH) (Hurler syndrome (IH))
CL Item
Neuronal ceroid – lipofuscinosis (Batten disease) (Neuronal ceroid – lipofuscinosis (Batten disease))
CL Item
I-cell disease (I-cell disease)
CL Item
Polysaccharide hydrolase abnormalities, unspecified (Polysaccharide hydrolase abnormalities, unspecified)
CL Item
Krabbe disease (globoid leukodystrophy) (Krabbe disease (globoid leukodystrophy))
CL Item
Sanfilippo (III) (Sanfilippo (III))
CL Item
Lesch-Nyhan (HGPRT deficiency) (Lesch-Nyhan (HGPRT deficiency))
CL Item
Scheie syndrome (IS) (Scheie syndrome (IS))
CL Item
Mannosidosis (Mannosidosis)
CL Item
Wolman disease (Wolman disease)
CL Item
Maroteaux-Lamy (VI) (Maroteaux-Lamy (VI))
CL Item
Other (Other)
CL Item
Inherited disorders of metabolism, not otherwise specified (Inherited disorders of metabolism, not otherwise specified)
Date of this HSCT
Item
Date of this HSCT
date
CL Item
Glanzmann thrombasthenia (1)
CL Item
Other inherited platelet abnormalities (2)
CL Item
Osteopetrosis (malignant infantile osteopetrosis) (3)
CL Item
Other osteoclast defects (4)
Date of this HSCT
Item
Date of this HSCT
date
CL Item
Histiocytic disorders, not otherwise specified (Histiocytic disorders, not otherwise specified )
CL Item
Familial erythro/haemophagocytic lymphohistiocytosis (FELH) (Familial erythro/haemophagocytic lymphohistiocytosis (FELH) )
CL Item
Langerhans Cell Histiocytosis (Histiocytosis-X) Haemophagocytosis (reactive or viral associated) (Langerhans Cell Histiocytosis (Histiocytosis-X) Haemophagocytosis (reactive or viral associated) )
CL Item
Malignant histiocytosis HISTIOCY (Malignant histiocytosis HISTIOCY )
CL Item
Other (Other)
Date of this HSCT
Item
Date of this HSCT
date
HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 10
Item Group
HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 10
EBMT Centre Identification Code (CIC)
Item
EBMT Centre Identification Code (CIC)
text
Hospital Unique Patient Number/Code
Item
Hospital Unique Patient Number/Code
text
Date of initial diagnosis
Item
Date of initial diagnosis
date
C2316983 (UMLS CUI [1])
Name of Referring Physician
Item
Name of Referring Physician
text
Address
Item
Address
text
Fax
Item
Fax
text
Email
Item
Email
text
Item
Classification CONNECTIVE TISSUE DISEASE
integer
CL Item
Systemic sclerosis (SS) (1)
CL Item
Systemic lupus erythematosus (SLE) (2)
Date of this HSCT
Item
Date of this HSCT
date
diffuse cutaneous
Item
Involvement/Clinical problem
boolean
limited cutaneous
Item
Involvement/Clinical problem
boolean
lung parenchyma
Item
Involvement/Clinical problem
boolean
pulmonary hypertension
Item
Involvement/Clinical problem
boolean
systemic hypertension
Item
Involvement/Clinical problem
boolean
renal (biopsy type
Item
Involvement/Clinical problem
boolean
oesophagus
Item
Involvement/Clinical problem
boolean
other GI tract
Item
Involvement/Clinical problem
boolean
Raynaud
Item
Involvement/Clinical problem
boolean
CREST
Item
Involvement/Clinical problem
boolean
diffuse cutaneous
Item
Indication for HSCT
boolean
limited cutaneous
Item
Indication for HSCT
boolean
lung parenchyma
Item
Indication for HSCT
boolean
pulmonary hypertension
Item
Indication for HSCT
boolean
systemic hypertension
Item
Indication for HSCT
boolean
renal (biopsy type
Item
Indication for HSCT
boolean
oesophagus
Item
Indication for HSCT
boolean
other GI tract
Item
Indication for HSCT
boolean
Raynaud
Item
Indication for HSCT
boolean
CREST
Item
Indication for HSCT
boolean
CL Item
No (1)
CL Item
Yes (2)
CL Item
Unknown (3)
CL Item
Normal/Negative (Normal/Negative )
CL Item
Elevated/Positive (Elevated/Positive )
CL Item
Not evaluated (Not evaluated)
CL Item
Normal/Negative (1)
CL Item
Elevated/Positive (2)
CL Item
Not evaluated (3)
Date of this HSCT
Item
Date of this HSCT
date
renal
Item
renal (biopsy type)
text
renal
Item
Presence
boolean
renal
Item
Indication for HSCT
boolean
CNS
Item
CNS type
text
CNS
Item
CNS Presence
boolean
CNS
Item
CNS Indication for HSCT
boolean
PNS
Item
PNS type
text
PNS
Item
PNS Presence
boolean
PNS
Item
PNS Indication for HSCT
boolean
lung
Item
lung Presence
boolean
lung
Item
lung Indication für HSCT
boolean
serositis
Item
serositis Presence
boolean
serositis
Item
serositis Infication for HSCT
boolean
arthritis
Item
arthritis Presence
boolean
arthritis
Item
arthritis Indication for HSCT
boolean
skin
Item
skin type
text
skin
Item
skin Presence
boolean
skin
Item
skin Indication for HSCT
boolean
haematological
Item
haematological type
text
haematological
Item
haematological Presence
boolean
haematological
Item
haematological Indication for HSCT
boolean
vasculitis
Item
vasculitis type
text
vasculitis
Item
vasculitis Presence
boolean
vasculitis
Item
vasculitis Indication for HSCT
boolean
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
CL Item
DNA (DNA )
CL Item
Normal/Negative (Normal/Negative )
CL Item
Elevated/Positive (Elevated/Positive )
CL Item
Not evaluated (Not evaluated)
CL Item
Other (Other)
HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 11
Item Group
HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 11
EBMT Centre Identification Code (CIC)
Item
EBMT Centre Identification Code (CIC)
text
Hospital Unique Patient Number/Code
Item
Hospital Unique Patient Number/Code
text
Date of Initial Diagnosis
Item
Date of Initial Diagnosis
date
Name of Referring Physician
Item
Name of Referring Physician
text
Address
Item
Address
text
Fax
Item
Fax
text
Email
Item
Email
text
C0013849 (UMLS CUI [1])
Item
UTOIMMUNE DISORDERS – II (main disease code 10) Classification
integer
Code List
UTOIMMUNE DISORDERS – II (main disease code 10) Classification
CL Item
Polymyositis- dermatomyositis (1)
CL Item
Sjögren syndrome (2)
CL Item
Antiphospholipid syndrome (3)
CL Item
Other type of connective tisue disease (4)
Date of this HSCT
Item
Date of this HSCT
date
proximal weakness
Item
proximal weakness Presence
boolean
proximal weakness
Item
proximal weakness Indication for HSCT
boolean
generalized weakness (including bulbar)
Item
generalized weakness (including bulbar) Presence
boolean
generalized weakness (including bulbar)
Item
generalized weakness (including bulbar) Indication for HSCT
boolean
pulmonary fibrosis
Item
pulmonary fibrosis Presence
boolean
pulmonary fibrosis
Item
pulmonary fibrosis Indication for HSCT
boolean
vasculitis
Item
vasculitis t<pe
text
vasculitis
Item
vasculitis Presence
boolean
vasculitis
Item
vasculitis Indication for HSCT
boolean
CL Item
typical biopsy (typical biopsy)
CL Item
typical EMG (typical EMG)
CL Item
typical rash (DM) (typical rash (DM))
CL Item
CPK elevated (CPK elevated)
CL Item
malignancy (malignancy)
Date of this HSCT
Item
Date of this HSCT
date
SICCA
Item
SICCA Presence
boolean
SICCA
Item
SICCA Indication for HSCT
boolean
exocrine gland swelling
Item
exocrine gland swelling Presence
boolean
exocrine gland swelling
Item
exocrine gland swelling Indication for HSCT
boolean
other organ lymphocytic infiltration
Item
other organ lymphocytic infiltration Presence
boolean
other organ lymphocytic infiltration
Item
other organ lymphocytic infiltration Indication for HSCT
boolean
lymphoma, paraproteinaemia
Item
lymphoma, paraproteinaemia Presence
boolean
lymphoma, paraproteinaemia
Item
lymphoma, paraproteinaemia Indication for HSCT
boolean
other clinical problem
Item
other, please specify
text
Date of this HSCT
Item
Date of this HSCT
date
hrombosis
Item
hrombosis type
text
hrombosis
Item
hrombosis Presence
boolean
hrombosis
Item
hrombosis Indication for HSCT
boolean
CNS
Item
CNS type
text
CNS
Item
CNS Presence
boolean
CNS
Item
CNS Indication for HSCT
boolean
abortion
Item
abortion Presence
boolean
abortion
Item
abortion Indication for HSCT
boolean
skin
Item
skin (livido, vasculitis) Presence
boolean
skin (livido, vasculitis)
Item
skin (livido, vasculitis) Indication for HSCT
boolean
haematological
Item
haematological type
text
haematological
Item
haematological Presence
boolean
haematological
Item
haematological Indication for HSCT
boolean
Other Involvement/Clinical problem
Item
if other, please specify
text
CL Item
No (1)
CL Item
Yes (2)
CL Item
Unknown (3)
CL Item
Normal/Negative (1)
CL Item
Elevated/Positive (2)
CL Item
Not evaluated (3)
CL Item
Normal/Negative (1)
CL Item
Elevated/Positive (2)
CL Item
Not evaluated (3)
Other Antibodies studied
Item
if yes, please specify
text
Date of this HSCT
Item
Date of this HSCT
date
HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 12
Item Group
HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 12
EBMT Centre Identification Code (CIC)
Item
EBMT Centre Identification Code (CIC)
text
Hospital Unique Patient Number/Code
Item
Hospital Unique Patient Number/Code
text
Date of Initial Diagnosis
Item
Date of Initial Diagnosis
date
Name of Referring Physician
Item
Name of Referring Physician
text
Address
Item
Address
text
Fax
Item
Fax
text
Email
Item
Email
text
C0013849 (UMLS CUI [1])
CL Item
Wegener granulomatosis (1)
CL Item
Classical polyarteritis nodosa (2)
Date of this HSCT
Item
Date of this HSCT
date
upper respiratory tract
Item
upper respiratory tract Presence
boolean
upper respiratory tract
Item
upper respiratory tract Indication for HSCT
boolean
pulmonary
Item
pulmonary Presence
boolean
pulmonary
Item
pulmonary Indication for HSCT
boolean
renal
Item
renal biobsy type
text
renal
Item
renal Presence
boolean
renal
Item
renal Indication for HSCT
boolean
skin
Item
skin Presence
boolean
skin
Item
skin Indication for HSCT
boolean
Other Involvement / Clinical problem
Item
If Other Involvement / Clinical problem please specify
text
CL Item
No (1)
CL Item
Yes (2)
CL Item
Unknown (3)
CL Item
Negative (1)
CL Item
Positive (2)
CL Item
Not evaluated (3)
Date of this HSCT
Item
Date of this HSCT
date
renal
Item
renal type
text
renal
Item
renal Presence
boolean
renal
Item
renal Indication for HSCT
boolean
mononeuritis multiplex
Item
mononeuritis multiplex Presence
boolean
mononeuritis multiplex
Item
mononeuritis multiplex Indication for HSCT
boolean
pulmonary haemorrhage
Item
pulmonary haemorrhage Presence
boolean
pulmonary haemorrhage
Item
pulmonary haemorrhage Indication for HSCT
boolean
skin
Item
skin presence
boolean
skin
Item
skin Indication for HSCT
boolean
GI tract
Item
GI tract Presence
boolean
GI tract
Item
GI tract Indication for HSCT
boolean
Involvement/Clinical problem
Item
if other Involvement/Clinical problem, please specify
text
CL Item
No (1)
CL Item
Yes (2)
CL Item
Unknown (3)
CL Item
Negative (1)
CL Item
Positive (2)
CL Item
Not evaluated (3)
CL Item
Negative (1)
CL Item
Positive (2)
CL Item
Not evaluated (3)
CL Item
Negative (Negative )
CL Item
Positive (Positive )
CL Item
Not evaluated (Not evaluated)
CL Item
Churg-Strauss (1)
CL Item
Giant cell arteritis (2)
CL Item
Takayasu (3)
CL Item
Behçet’s syndrome (4)
CL Item
Overlap necrotising arteritis (5)
CL Item
Other (6)
Date of this HSCT
Item
Date of this HSCT
date
HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 13
Item Group
HSCT - Minimum Essential Data - A First report - 100 days after HSCT DISEASE CLASSIFICATION SHEET 13
EBMT Centre Identification Code (CIC)
Item
EBMT Centre Identification Code (CIC)
text
Hospital Unique Patient Number/Code
Item
Hospital Unique Patient Number/Code
text
Date of Initial Diagnosis
Item
Date of Initial Diagnosis
date
Name of Referring Physician
Item
Name of Referring Physician
text
Address
Item
Address
text
Fax
Item
Fax
text
Email
Item
Email
text
C0013849 (UMLS CUI [1])
Item
AUTOIMMUNE DISORDERS – IV (main disease code 10) ARTHRITIS
integer
Code List
AUTOIMMUNE DISORDERS – IV (main disease code 10) ARTHRITIS
CL Item
Rheumatoid arthritis (Rheumatoid arthritis)
CL Item
Psoriatic arthritis/psoriasis (Psoriatic arthritis/psoriasis)
CL Item
Juvenile idiopathic arthritis (JIA), systemic (Stills disease) (Juvenile idiopathic arthritis (JIA), systemic (Stills disease))
CL Item
Juvenile idiopathic arthritis (JIA), articular (Juvenile idiopathic arthritis (JIA), articular)
CL Item
Juvenile idiopathic arthritis (Juvenile idiopathic arthritis)
CL Item
Other (Other)
Date of this HSCT
Item
Date of this HSCT
date
destructive arthritis
Item
destructive arthritis Presence
boolean
destructive arthritis
Item
destructive arthritis Indication for HSCT
boolean
eye
Item
eye type
text
eye
Item
eye Presence
boolean
eye
Item
eye Indication for HSCT
boolean
pulmonary
Item
pulmonary Presence
boolean
pulmonary
Item
pulmonary Indication for HSCT
boolean
extra articular
Item
if extra articular, please specify
text
extra articular
Item
extra articular Presence
boolean
extra articular
Item
extra articular Indication for HSCT
boolean
Date of this HSCT
Item
Date of this HSCT
date
destructive arthritis
Item
destructive arthritis Presence
boolean
destructive arthritis
Item
destructive arthritis Indication for HSCT
boolean
psoriasis
Item
psoriasis Presence
text
psoriasis
Item
psoriasis Indication for HSCT
boolean
Date of this HSCT
Item
Date of this HSCT
date
MULTIPLE SCLEROSIS
Item
MULTIPLE SCLEROSIS
boolean
Date of this HSCT
Item
Date of this HSCT
date
CL Item
primary progressive VDISESTA (1)
CL Item
secondary progressive (2)
CL Item
relapsing/remitting (3)
CL Item
other (4)
CL Item
Myasthenia gravis (Myasthenia gravis )
CL Item
Amyotrophic lateral sclerosis (ALS) (Amyotrophic lateral sclerosis (ALS))
CL Item
Chronic inflammatory demyelinating polyneuropathy (CIDP) (Chronic inflammatory demyelinating polyneuropathy (CIDP))
CL Item
Other autoimmune neurological disorder (Other autoimmune neurological disorder)
Other autoimmune neurological disorder
Item
Other autoimmune neurological disorder, specify
text
Date of this HSCT
Item
Date of this HSCT
date
CL Item
Idiopathic thrombocytopenic purpura (ITP) (1)
CL Item
Haemolytic anaemia Autoimmune lymphoproliferative syndrome (primary diagnosis, not subsequent to HSCT) (2)
CL Item
Evan syndrome (3)
CL Item
other autoimmune cytopenia (4)
other autoimmune cytopenia
Item
other autoimmune cytopenia, specify
text
Date of this HSCT
Item
Date of this HSCT
date
CL Item
Crohn’s disease (Crohn’s disease)
CL Item
Ulcerative colitis (Ulcerative colitis)
CL Item
Other autoimmune bowel disease (Other autoimmune bowel disease)
Other autoimmune bowel disease
Item
Other autoimmune bowel disease, specify
text
Date of this HSCT
Item
Date of this HSCT
date
Item Group
HSCT - Minimum Essential Data - A Follow up report: 1 year post transplant and annually thereafter
PRIMARY DISEASE DIAGNOSIS
Item
PRIMARY DISEASE DIAGNOSIS
text
EBMT Code (CIC)
Item
EBMT Code (CIC)
text
Hospital:
Item
Hospital:
text
Klinik
Item
Hospital
text
C0019994 (UMLS CUI [1])
Unit
Item
Unit
text
Contact person
Item
Name of contact person
text
C0337611 (UMLS CUI [1])
Date of this Report
Item
Date of this Report
date
Item
Patient following national / international study / trial
integer
Code List
Patient following national / international study / trial
CL Item
Yes (1)
CL Item
No (2)
CL Item
Unknown (3)
Name of study / trial
Item
Name of study / trial
text
Hospital Unique Patient Number/Code
Item
Hospital Unique Patient Number/Code (Compulsory, registrations will not be accepted without this item)
text
Initials
Item
Initials
text
Date of Birth
Item
Date of Birth
date
CL Item
Male (1)
CL Item
Female (2)
Date of the most recent transplant before this follow up
Item
Date of the most recent transplant before this follow up
date
Item
Best disease status (response) after transplant (prior to treatment modification in response to a post transplant disease assessment)
integer
Code List
Best disease status (response) after transplant (prior to treatment modification in response to a post transplant disease assessment)
CL Item
Continued complete remission (CR) (1)
CL Item
CR achieved (2)
CL Item
Never in CR: Date assessed (3)
CL Item
Previously reported (4)
Date achieved
Item
Date achieved
date
Date assessed
Item
Date assessed
date
Date of last follow up or death
Item
Date of last follow up or death
date
Item
Chronic Graft Versus Host Disease present during this period (allografts only)
text
Code List
Chronic Graft Versus Host Disease present during this period (allografts only)
CL Item
No (never) (No (never))
CL Item
Yes (Yes)
CL Item
Yes, First episode since last HSCT (Yes, First episode since last HSCT)
CL Item
Yes, Recurrence (Yes, Recurrence)
CL Item
Continuous since last reported episode (Continuous since last reported episode)
CL Item
Resolved since last report (currently absent) (Resolved since last report (currently absent))
Date of diagnosis of cGvHD
Item
Date of diagnosis of cGvHD
date
Date first evidence of cGVHD during this period
Item
Date first evidence of cGVHD during this period
date
CL Item
Limited (1)
CL Item
Extensive (2)
CL Item
Unknown (3)
Late graft failure (allografts only)
Item
Late graft failure (allografts only)
boolean
Did a secondary malignancy, lymphoproliferative or myeloproliferative disorder occur?
Item
Did a secondary malignancy, lymphoproliferative or myeloproliferative disorder occur?
boolean
Date of diagnosis
Item
Date of diagnosis
date
Diagnosis:
Item
Diagnosis:
text
ADDITIONAL DISEASE TREATMENT INCLUDING CELL THERAPY
Item
ADDITIONAL DISEASE TREATMENT INCLUDING CELL THERAPY
boolean
ADDITIONAL DISEASE TREATMENT INCLUDING CELL THERAPY
Item
Date
date
Additional cell infusion (not HSCT or auto re-infusion)
Item
Additional cell infusion (not HSCT or auto re-infusion)
boolean
CL Item
No (1)
CL Item
Yes (2)
CL Item
Yes Plannes (3)
CL Item
Yes Not plannes (4)
CL Item
No (No)
CL Item
Yes (Yes)
CL Item
Continuous progression since HSCT (Continuous progression since HSCT)
Date assessed
Item
Date assessed
date
Date first seen
Item
Date first seen
date
Item
Relapse/progression detected by clinical/haematological method
integer
Code List
Relapse/progression detected by clinical/haematological method
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
Date assessed
Item
Date assessed
date
Date first seen
Item
Date first seen
date
Item
Relapse/progression detected by cytogenetic method
integer
Code List
Relapse/progression detected by cytogenetic method
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
Date assessed
Item
Date assessed
boolean
Date first seen
Item
Date first seen
date
Item
Relapse/progression detected by molecular method
integer
Code List
Relapse/progression detected by molecular method
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
Date assessed
Item
Date assessed
date
Date first seen
Item
Date first seen
date
Item
Was disease detected by clinical/haematological method?:
integer
Code List
Was disease detected by clinical/haematological method?:
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
Last date assessed
Item
Last date assessed
date
Was disease detected by cytogenetic/FISH method?:
Item
Was disease detected by cytogenetic/FISH method?:
boolean
Considered disease relapse/progression
Item
Considered disease relapse/progression
boolean
Last date assessed
Item
Last date assessed
date
Item
Was disease detected by molecular method? Fill in only for acute and chronic LEUKAEMIAS
integer
Code List
Was disease detected by molecular method? Fill in only for acute and chronic LEUKAEMIAS
CL Item
No (1)
CL Item
Yes (2)
CL Item
Not evaluated (3)
Considered disease relapse/progression
Item
Considered disease relapse/progression
boolean
Last date assessed
Item
Last date assessed
date
Item
Has patient or partner become pregnant after this transplant?
integer
Code List
Has patient or partner become pregnant after this transplant?
CL Item
No (1)
CL Item
Yes (2)
CL Item
Unknown (3)
CL Item
alive (0)
CL Item
dead (1)
Check here if patient lost to follow up
Item
Check here if patient lost to follow up
boolean
CL Item
Relapse or Progression (if indication: primary disease) (1)
CL Item
HSCT related (if applicable) (2)
CL Item
Cell Therapy (3)
CL Item
Other (4)
CL Item
Unknown (5)
CL Item
GVHD GVH (GVHD GVH )
CL Item
Cardiac Toxicity CTX (Cardiac Toxicity CTX)
CL Item
Rejection/Poor graft function REJ (Rejection/Poor graft function REJ )
CL Item
Infection INF (Infection INF)
CL Item
Pulmonary toxicity PTX (Pulmonary toxicity PTX )
CL Item
Veno occlusive disorder (Veno occlusive disorder)
CL Item
Other (Other)
HSCT Related Cause
Item
HSCT Related Cause if other, please specify
text
Item Group
HSCT - Minimum Essential Data - A Follow up report: Annual follow up CELL INFUSION (CI) SHEET
EBMT Centre Identification Code (CIC)
Item
EBMT Centre Identification Code (CIC)
text
C2348585 (UMLS CUI [1])
Hospital Unique Patient Number/Code
Item
Hospital Unique Patient Number/Code
text
Date of first infusion
Item
Date of first infusion
date
CL Item
CR (1)
CL Item
Not on CR (2)
CL Item
Not evaluated (3)
Date of first infusion
Item
Date of first infusion
date
CL Item
CR (1)
CL Item
Not in CR (2)
CL Item
Not evaluated (3)
Item
Cell infusion (CI) regimen (not HSCT or autologous stem cell re-infusion) Type of cell(s): (check all that apply)
text
Code List
Cell infusion (CI) regimen (not HSCT or autologous stem cell re-infusion) Type of cell(s): (check all that apply)
CL Item
Lymphocytes (DLI) (Lymphocytes (DLI) )
CL Item
Mesenchymal (Mesenchymal )
CL Item
Fibroblasts (Fibroblasts )
CL Item
Dendritic cells (Dendritic cells )
CL Item
Other (Other)
Cell infusion (CI) regimen
Item
if other, please specify
text
Chronological no. of CI for this patient
Item
Chronological no. of CI for this patient
text
CL Item
Planned (1)
CL Item
Prophylactic (2)
CL Item
Mixed chimaerism (3)
CL Item
Loss / decreased chimaerism (4)
CL Item
Treatment of GvHD (5)
CL Item
Treatment for disease (6)
CL Item
Treatment PTLD, EBV lymphoma (7)
CL Item
Treatment viral infection (8)
CL Item
Other (9)
Infusion count
Item
Number of infusions within 10 weeks (count only infusions that are part of same regimen and given for the same indication)
float
C0574032 (UMLS CUI [1,1])
C0750480 (UMLS CUI [1,2])
C0750480 (UMLS CUI [1,2])
CL Item
0 (1)
CL Item
1 (2)
CL Item
2 (3)
CL Item
3 (4)
CL Item
4 (5)
CL Item
Present but grade unknown (6)